G-CSF (Granulocyte Colony Stimulating Factors) Global Market Research Report 2022 - ResearchAndMarkets.com

The "G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2022: By Type, By Application, By Product" report has been added to ResearchAndMarkets.com's offering.

The global G-CSF (granulocyte colony stimulating factors) market is expected to grow from $7.37 billion in 2021 to $7.99 billion in 2022 at a compound annual growth rate (CAGR) of 8.5%. The market is expected to reach $9.48 billion in 2026 at a CAGR of 4.4%.

Major players in the G-CSF (Granulocyte Colony Stimulating Factors) market are BioCad, Teva Pharmaceuticals, Pfizer, Intas Pharmaceuticals, Novartis AG, Stada Arzneimittel, Dong-A Socio Group, Amgen, Dr. Reddy's Laboratories and Celltrion Inc.

Where is the largest and fastest growing market for the g-csf (granolocyte colony stimulating factors)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The G-CSF (Granolocyte Colony Stimulating Factors) market global report answers all these questions and many more.

The G-CSF (Granulocyte Colony Stimulating Factors) market consists of sales of G-CSF drugs and relates services. Granulocyte colony-stimulating factor is a drug used to treat neutropenia, a disorder in which there is a lower-than-average number of white blood cells, caused by certain forms of chemotherapy.

The main types of G-CSF are lenograstim (granocyte), filgrastim (neupogen, zarzio, nivestim, accofil), long acting (pegylated) filgrastim (pegfilgrastim, neulasta, pelmeg, ziextenco) and lipegfilgrastim (lonquex). Lenograstim is a glycosylated recombinant therapeutic drug that is chemically similar to or identical to a naturally occurring human granulocyte colony-stimulating factor (G-CSF). The different products include tablet, capsule, others and is used in oncological diseases, blood disorders, growth hormone deficiencies, chronic and autoimmune disorders, others.

The increasing prevalence of cancer is a key factor driving the growth of the G-CSF (Granulocyte Colony Stimulating Factors) market. Cancer is considered to be the second major cause of death, with around 1 in 6 deaths due to cancer worldwide. According to the International Agency for Research on Cancer (IARC), by 2040, the global burden is projected to increase to 27.5 million active cancer incidents and 16.3 million cancer deaths primarily due to population growth and ageing.

About 70% of deaths from cancer occur in low- and middle-income countries. G-CSF is a class of growth factor which produces white blood cells in the bone marrow to minimize the risk of infection and sepsis. In cancer patients, G-CSF accelerates recovery and reduces mortality from neutropenia after chemotherapy for cancer. It can also reduce infection after certain forms of treatment for cancer. Therefore, the increasing prevalence of cancer is expected to drive the growth of the G-CSF market.

The increasing demand for prophylaxis granulocyte colony-stimulating factor (G-CSF) is another key factor driving the growth of the granulocyte-colony stimulating factor market. The prophylaxis with G-CSF decreases the occurrence of febrile neutropenia (FN), allowing patients to receive and stay on myelosuppressive chemotherapy.

The current use of G-CSF prophylaxis offers significant benefits including reducing incidents of febrile neutropenia by 3.3 million and cases of chemotherapy reduced dosage intensity by less than 85%, over the next 10 years. Therefore, the increasing demand for prophylaxis granulocyte colony-stimulating factor (G-CSF) is expected to drive the growth of the granulocyte-colony stimulating factor market.

The high cost is a key factor limiting the growth of the G-CSF market. Improved chemotherapy administration is responsible for the rise in instant medical expenses in breast cancer patients receiving primary prophylactic (PP) G-CSF. According to a study conducted by the American Journal of Managed Care, PPG-CSF administration in the first chemotherapy class was associated with a 57% increase in total Medicare costs during the study period, despite a fall in medical costs for neutropenia.

Around 42% of the increase can be attributed to the rise in the costs of chemotherapy. Each shot of PPG-CSF costs more than $250. Therefore, the high cost is expected to hinder the growth of the G-CSF (Granulocyte Colony Stimulating Factors) market.

Key Topics Covered:

1. Executive Summary

2. G-CSF (Granulocyte Colony Stimulating Factors) Market Characteristics

3. G-CSF (Granulocyte Colony Stimulating Factors) Market Trends And Strategies

4. Impact Of COVID-19 On G-CSF (Granulocyte Colony Stimulating Factors)

5. G-CSF (Granulocyte Colony Stimulating Factors) Market Size And Growth

5.1. Global G-CSF (Granulocyte Colony Stimulating Factors) Historic Market, 2016-2021, $ Billion

5.1.1. Drivers Of The Market

5.1.2. Restraints On The Market

5.2. Global G-CSF (Granulocyte Colony Stimulating Factors) Forecast Market, 2021-2026F, 2031F, $ Billion

5.2.1. Drivers Of The Market

5.2.2. Restraints On the Market

6. G-CSF (Granulocyte Colony Stimulating Factors) Market Segmentation

6.1. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

• Lenograstim (Granocyte)
• Filgrastim (Neupogen, Zarzio, Nivestim, Accofil)
• Long acting (pegylated) filgrastim (pegfilgrastim, Neulasta, Pelmeg, Ziextenco)
• Lipegfilgrastim (Lonquex)

6.2. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

• Oncological Diseases
• Blood Disorders
• Growth Hormone Deficiencies
• Chronic and Autoimmune Disorders
• Others

6.3. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

• Tablet
• Capsule
• Others

7. G-CSF (Granulocyte Colony Stimulating Factors) Market Regional And Country Analysis

7.1. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

7.2. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

Companies Mentioned

• BioCad
• Teva Pharmaceuticals
• Pfizer
• Intas Pharmaceuticals
• Novartis AG
• Stada Arzneimittel
• Dong-A Socio Group
• Amgen
• Dr. Reddy's Laboratories
• Celltrion inc.
• Emcure Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/i4xrcj

View source version on businesswire.com: https://www.businesswire.com/news/home/20220630005574/en/